Items where authors include "Dorr, MB"

Article

Goldstein, EJC, Citron, DM, Gerding, DN et al. (5 more authors) (2020) Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II. Clinical Infectious Diseases, 71 (4). ciz1151. pp. 1102-1105. ISSN 1058-4838

Kelly, CP, Poxton, IR, Shen, J et al. (7 more authors) (2020) Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection. Clinical Infectious Diseases, 71 (1). pp. 81-86. ISSN 1058-4838

Shen, J, Mehrotra, DV, Dorr, MB et al. (9 more authors) (2020) Genetic Association Reveals Protection against Recurrence of Clostridium difficile Infection with Bezlotoxumab Treatment. mSphere, 5 (3). e00232-20. ISSN 2379-5042

Zeng, Z, Zhao, H, Dorr, MB et al. (6 more authors) (2020) Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. Anaerobe, 61. 102137. ISSN 1075-9964

Wilcox, MH orcid.org/0000-0002-4565-2868, Rahav, G, Dubberke, ER et al. (7 more authors) (2019) Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II. Open Forum Infectious Diseases, 6 (8). ofz293. ISSN 2328-8957

Kelly, CP, Wilcox, MH orcid.org/0000-0002-4565-2868, Glerup, H et al. (4 more authors) (2018) Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease. Gastroenterology, 155 (4). pp. 1270-1271. ISSN 0016-5085